J Rhinol.  2016 May;23(1):6-16. 10.18787/jr.2016.23.1.6.

Efficacy and Safety of Newly Developed Korean Continuous Positive Airway Pressure Treatment in Patients with Obstructive Sleep Apnea Syndrome

  • 1Department of Otorhinolaryngology, School of Medicine, Keimyung University, Daegu, Korea.
  • 2Department of Otorhinolaryngology-Head and Neck Surgery, Seoul, Korea. hysiam.kim@samsung.com
  • 3Biostatistics Unit, Samsung Biomedical Reserch Institute, Seoul, Korea.
  • 4Division of Pulmonary and Critical Care Medicine, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea.


Obstructive sleep apnea syndrome(OSAS) is characterized by repeated apnea, hypopnea, and micro-arousals during sleep. Among various treatment modalities of OSAS, continuous positive airway pressure(CPAP) treatment is the most effective and successful. The aim of this study was to compare efficacy and safety of newly developed Korean CPAP with standard CPAP in OSAS patients. MATERIALS AND METHOD: In total, 20 of 26 recruited OSAS patients completed the study. All subjects first used the standard CPAP for 4 weeks. After an at least 2 week wash-out period, the subjects used the newly developed CPAP for 4 weeks. Polysomnography, questionnaires associated with sleep, lipid profile, pulmonary function test, cardiac marker, and physical examinations were evaluated at baseline and were followed-up after each treatment.
After treatment with the newly developed CPAP, the apnea-hypopnea index was decreased from 53.2/hr to 2.5/hr and was equivalent to that of the standard CPAP. Most of the changes in questionnaire scores, laboratory findings, and physical examinations after newly developed CPAP treatment were equivalent to those with standard CPAP. No serious adverse events were observed during the study.
The efficacy and safety of a newly developed CPAP are equivalent to those of standard CPAP in OSAS patients.


OSAS; AHI; Efficacy; Safety; Newly developed Korean CPAP
Full Text Links
  • JR
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr